MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$11,009K
Net Income
-$7,545K
Net Profit Margin
-68.53%
EPS
-$1.51
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Collaboration revenue
11,009
3,056
2,754
18,161*
Research and development
12,182
16,218
18,341
25,575*
General and administrative
6,303
7,415
8,925
10,263*
Restructuring expenses
191
3,940
-
-
Total operating expenses
18,676
27,573
27,266
35,837*
Interest income
516
895
1,164
2,224*
Interest expense
394
674
775
921*
Total other income, net
122
221
389
1,303*
Loss before income taxes
-7,545
-
-
-
Income tax expense
0
-
-
-836*
Net loss
-7,545
-24,296
-24,123
-15,538*
Unrealized gain (loss) on marketable securities, net of tax
0
0
-10
-173*
Comprehensive loss
-7,545
-24,296
-24,133
-15,712
Basic EPS
-1.51
-4.87
-0.19
-0.128
Diluted EPS
-1.51
-4.87
-0.19
-0.128
Basic Average Shares
4,992,639
4,986,784
124,466,113
122,456,752
Diluted Average Shares
4,992,639
4,986,784
124,466,113
122,456,752
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$7,545K
(33.84%↑ Y/Y)
Net loss
-$7,545K
(34.40%↑ Y/Y)
Interest income
$516K
(-73.83%↓ Y/Y)
Loss before income
taxes
-$7,545K
(31.92%↑ Y/Y)
Collaboration revenue
$11,009K
(-12.61%↓ Y/Y)
Total other income,
net
$122K
(-87.63%↓ Y/Y)
Interest expense
$394K
(-60.04%↓ Y/Y)
Total operating
expenses
$18,676K
(-24.29%↓ Y/Y)
Research and development
$12,182K
(-17.71%↓ Y/Y)
General and
administrative
$6,303K
(-36.10%↓ Y/Y)
Restructuring expenses
$191K
Buy us a coffee
Mersana Therapeutics, Inc. (MRSN)
Mersana Therapeutics, Inc. (MRSN)